Canadian AIDS Treatment Information Exchange


CATIE's Vision
CATIE envisions a future free of HIV and hepatitis C.

CATIE's Mission
CATIE is Canada's source for accessible, evidence-based information about HIV and hepatitis C prevention, testing, care, treatment and support. CATIE strengthens the national response to HIV and hepatitis C by fostering collaboration and capacity among people living with HIV and/or hepatitis C and other affected populations, frontline service providers and researchers to reduce transmission and improve health and well-being.

Our Services
CATIE is Canada's source for up-to-date, unbiased information about HIV and hepatitis C. We connect people living with HIV or hepatitis C, at-risk communities, healthcare providers and community organizations with the knowledge, resources and expertise to reduce transmission and improve quality of life.

Connect With the Tools You Need
The latest news about HIV and hepatitis C treatment and prevention in clear language

  • Accurate online information
  • Research updates
  • Confidential inquiry line

Resources developed in partnership with organizations across Canada

  • Free publications
  • Program tools
  • Case studies

Events for service providers to share approaches and lessons learned

  • CATIE Forum
  • Regional conferences
  • Learning Institutes

Educational opportunities in person and online

  • Webinars
  • Workshops
  • Training courses

Order a CATIE Brochure
This bilingual brochure provides a brief overview of CATIE's programs and services. Order a copy from the CATIE Ordering Centre.

CATIE's History

Read more about CATIE's history and milestones.

How to Reach CATIE

CATIE (Canadian AIDS Treatment Information Exchange)
555 Richmond Street West, Suite 505
Box 1104
Toronto, Ontario M5V 3B1 Canada

Phone: 416.203.7122 or 1.800.263.1638
Fax: 416.203.8284

Categories Covered:Other Populations, Women, HIV Treatment and Medical Care, Nutrition and Fitness, People Over 50, HIV Epidemiology, Adverse Events, Comorbidities, and HIV, HIV and Mental Health Care, HIV Advocates in the Spotlight, Gay Men, Tenofovir Disoproxil Fumarate (Viread), Switching or Stopping HIV Treatment, Managing People Newly Diagnosed With HIV, HIV Care Continuum, HIV in the Arts, Providing Quality HIV Care, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), HIV Testing, Managing Primary/Acute HIV Infection, HIV Prevention Methods, Living Well With HIV, Lopinavir/Ritonavir (Kaletra), Raltegravir (Isentress), Kidney Issues and HIV, Non-HIV Sexually Transmitted Infections, HIV Treatment Strategies, PrEP (HIV Pre-Exposure Prophylaxis), HIV in Specific Countries, Mental Health, Newly Diagnosed, Relationships and Sex, HIV/AIDS Basics, HIV Education and Risk Management, Body Fat, Lipodystrophy and HIV, HIV, Discrimination, and Law, Finding HIV Support Groups and Services, HIV Treatments in Development, HIV Care and Services Outside the US, History of HIV/AIDS, Starting HIV Treatment and Medical Care, HIV in Film, TV, and Media, Latinx People, HIV Basic Science and Pathogenesis, Cobicistat/Emtricitabine/Elvitegravir/Tenofovir Alafenamide (Genvoya, E/C/F/TAF), Pregnancy, Childbirth, and HIV, Managing Long-Term HIV Survivors, PEP (HIV Post-Exposure Prophylaxis), Rilpivirine (Edurant), Efavirenz (Sustiva, Stocrin), Dental/Mouth Issues and HIV, Physical Health Issues, Dolutegravir (Tivicay), Substance Use and Harm Reduction for HIV, PrEP (HIV Pre-Exposure Prophylaxis), HIV Advocacy and Activism, HIV/AIDS Outside the U.S., HIV Stigma and Discrimination, Bone Problems and HIV, FDA-Approved HIV Medications, Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy, B/F/TAF), HIV Prevention and Transmission, Hormone-Related Issues and HIV, Darunavir (Prezista), People Under 30, HIV Prevention for People With HIV, HIV in Books and Publishing, Viramune (Nevirapine), First-Line HIV Treatment, Meeting the Costs of HIV Care, HIV/AIDS Statistics, Ritonavir (Norvir), Emtricitabine/Tenofovir Alafenamide (Descovy), Heart Disease and HIV, Maraviroc (Selzentry, Celsentri), Neuorlogical (Brain/Nerve) Issues and HIV, Conceiving and Having a Baby, Abacavir (Ziagen), Etravirine (Intelence), Tools and Tips for HIV Advocacy, Spirituality and Religion, HIV Case Management and Social Work, Disclosing Your HIV Status, Managing HIV Drug Resistance, Nevirapine (Viramune), Didanosine (ddI, Videx), Anemia, Fatigue, and HIV, Atazanavir (Reyataz), Enfuvirtide (T-20, Fuzeon), Personal Stories from the HIV Community, Gastrointestinal (Gut) Issues and HIV, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Managing HIV Drug Resistance, Non-Medical HIV Prevention, Tuberculosis and HIV, Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Cobicistat (Tybost), Pediatric HIV Care, Understanding HIV-Related Lab Tests, African-Americans, Saquinavir (Invirase)

Latest by Canadian AIDS Treatment Information Exchange

Overdoses and Smoking Are Taking the Lives of People With HIV Who Have Been Cured of Hepatitis C

"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Gay Men, Substance Use, and Harm Reduction: It's Time to Act

"Placing more attention on meeting the sexual health and holistic wellness needs of gay men affected by sexualized substance use is critical," writes the associate director of Ontario's Gay Men's Sexual Health Alliance.

By Dane Griffiths for Canadian AIDS Treatment Information Exchange

De-Simplifying Single-Tablet Regimens for HIV Treatment

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Monkey Study Uncovers the Potential for Vesatolimod and Antibodies in HIV Cure Research

Researchers hope that by interacting with the toll-like receptor protein TLR-7 an experimental drug can help increase the immune system's ability to sense and attack HIV and HIV-infected cells.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Italian Study Explores Dual Drug Regimens as Maintenance Treatment

Researchers found that around 90% of participants who were switched to a dual drug regimen maintained a suppressed viral load over the course of the study.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Combinations of Super Antibodies May Keep HIV at Bay

The results from this pilot study are exciting and raise many issues that need to be taken into account for future studies of broadly neutralizing antibodies.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Smartphone Intervention Found Helpful for Young Men Taking PrEP

U.S. researchers have developed PrEPmate, a text messaging service to increase PrEP adherence.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

PositiveLinks: Mobile Intervention for People With HIV

Study results of an intervention that includes a custom smartphone app tailored to the needs and preferences of a rural population of people with HIV living in the southern U.S.

By Canadian AIDS Treatment Information Exchange